This is a news story, published by Sky News, that relates primarily to Paul Read news.
For more Paul Read news, you can click here:
more Paul Read newsFor more medical innovations news, you can click here:
more medical innovations newsFor more news from Sky News, you can click here:
more news from Sky NewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like medical innovations news, you might also like this article about
brain cancer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest recurrent glioblastoma news, Primary brain tumours news, medical innovations news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
deadly brain tumourSky News
•73% Informative
Paul Read , 62 , was diagnosed with recurrent glioblastoma - a type of brain cancer which kills within 18 months .
He was offered chance to be first patient in a clinical trial aiming to cure the disease.
Surgeons remove tumour before implanting device under the scalp which connects to tumour via tube.
Nuclear medicine team inject drug - ATT001 - directly into tumour to deliver radioactivity.
Drug causes lethal damage to cells but leaves healthy tissue unaffected.
VR Score
71
Informative language
69
Neutral language
44
Article tone
informal
Language
English
Language complexity
40
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links